Mozobil Approval History
- FDA approved: Yes (First approved December 15th, 2008)
- Brand name: Mozobil
- Generic name: plerixafor
- Company: Genzyme Corporation
- Treatment for: Bone Marrow Transplantation
Mozobil (plerixafor) is a small molecule CXCR4 chemokine receptor antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
Development History and FDA Approval Process for Mozobil
|Dec 16, 2008||FDA Approves Genzyme's Mozobil|
|Sep 23, 2008||Genzyme Announces FDA Priority Review for Mozobil New Drug Application|
|Jun 17, 2008||Genzyme Files Applications for Approval of Mozobil in the United States and Europe|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.